CGX 1160

Drug Profile

CGX 1160

Alternative Names: Contulakin-G

Latest Information Update: 29 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cognetix
  • Class Analgesics; Antiepileptic drugs
  • Mechanism of Action Neurotensin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 07 Jul 2005 CGX 1160 has received Orphan Drug Status for Neuropathic pain in USA
  • 22 Oct 2004 Cognetix seeks a partner for the late-stage development and marketing of CGX 1160 (
  • 11 Dec 2002 Clinical data from a media release have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top